| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 08/01/2024 | 13h00 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:PNT | POINT Biopharma Global Inc |
| 03/01/2024 | 06h15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:PNT | POINT Biopharma Global Inc |
| 03/01/2024 | 06h15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h41 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h37 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 23h35 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 15h44 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 15h43 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 15h42 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 15h41 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 15h39 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 14h54 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PNT | POINT Biopharma Global Inc |
| 27/12/2023 | 14h31 | PR Newswire (US) | Lilly Completes Acquisition of POINT Biopharma | NASDAQ:PNT | POINT Biopharma Global Inc |
| 18/12/2023 | 14h14 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:PNT | POINT Biopharma Global Inc |
| 18/12/2023 | 13h30 | GlobeNewswire Inc. | Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer | NASDAQ:PNT | POINT Biopharma Global Inc |
| 18/12/2023 | 12h45 | PR Newswire (US) | Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 | NASDAQ:PNT | POINT Biopharma Global Inc |
| 05/12/2023 | 12h25 | IH Market News | Moody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and More | NASDAQ:PNT | POINT Biopharma Global Inc |
| 04/12/2023 | 13h22 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:PNT | POINT Biopharma Global Inc |
| 04/12/2023 | 12h45 | PR Newswire (US) | Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 | NASDAQ:PNT | POINT Biopharma Global Inc |
| 17/11/2023 | 13h05 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:PNT | POINT Biopharma Global Inc |
| 17/11/2023 | 12h45 | PR Newswire (US) | Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 | NASDAQ:PNT | POINT Biopharma Global Inc |
| 15/11/2023 | 13h00 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:PNT | POINT Biopharma Global Inc |
| 14/11/2023 | 22h33 | PR Newswire (US) | Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma | NASDAQ:PNT | POINT Biopharma Global Inc |
| 13/11/2023 | 13h30 | GlobeNewswire Inc. | POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights | NASDAQ:PNT | POINT Biopharma Global Inc |
| 13/11/2023 | 13h15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:PNT | POINT Biopharma Global Inc |